vs
Side-by-side financial comparison of Metallus Inc. (MTUS) and Bio-Techne (TECH). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($308.3M vs $295.9M, roughly 1.0× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 1.8%, a 11.1% gap on every dollar of revenue. On growth, Metallus Inc. posted the faster year-over-year revenue change (9.9% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 2.3%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
MTUS vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $308.3M | $295.9M |
| Net Profit | $5.4M | $38.0M |
| Gross Margin | 8.1% | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 1.8% | 12.8% |
| Revenue YoY | 9.9% | -6.4% |
| Net Profit YoY | 315.4% | 68.3% |
| EPS (diluted) | $0.13 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $308.3M | — | ||
| Q4 25 | $267.3M | $295.9M | ||
| Q3 25 | $305.9M | — | ||
| Q2 25 | $304.6M | $317.0M | ||
| Q1 25 | $280.5M | $316.2M | ||
| Q4 24 | $240.5M | $297.0M | ||
| Q3 24 | $227.2M | $289.5M | ||
| Q2 24 | $294.7M | $306.1M |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-14.3M | $38.0M | ||
| Q3 25 | $8.1M | — | ||
| Q2 25 | $3.7M | $-17.7M | ||
| Q1 25 | $1.3M | $22.6M | ||
| Q4 24 | $-21.4M | $34.9M | ||
| Q3 24 | $-5.9M | $33.6M | ||
| Q2 24 | $4.6M | $40.6M |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 2.2% | 64.6% | ||
| Q3 25 | 11.4% | — | ||
| Q2 25 | 10.6% | 62.7% | ||
| Q1 25 | 7.8% | 67.9% | ||
| Q4 24 | 4.5% | 65.3% | ||
| Q3 24 | 5.3% | 63.2% | ||
| Q2 24 | 8.2% | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | -7.7% | 18.4% | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 2.8% | -7.5% | ||
| Q1 25 | 1.0% | 12.2% | ||
| Q4 24 | -10.1% | 16.0% | ||
| Q3 24 | -3.1% | 13.8% | ||
| Q2 24 | 2.1% | 15.0% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | -5.3% | 12.8% | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 1.2% | -5.6% | ||
| Q1 25 | 0.5% | 7.1% | ||
| Q4 24 | -8.9% | 11.7% | ||
| Q3 24 | -2.6% | 11.6% | ||
| Q2 24 | 1.6% | 13.3% |
| Q1 26 | $0.13 | — | ||
| Q4 25 | $-0.34 | $0.24 | ||
| Q3 25 | $0.19 | — | ||
| Q2 25 | $0.09 | $-0.11 | ||
| Q1 25 | $0.03 | $0.14 | ||
| Q4 24 | $-0.46 | $0.22 | ||
| Q3 24 | $-0.13 | $0.21 | ||
| Q2 24 | $0.10 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.0M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $683.0M | $2.0B |
| Total Assets | $1.1B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $156.7M | $172.9M | ||
| Q3 25 | $191.5M | — | ||
| Q2 25 | $190.8M | $162.2M | ||
| Q1 25 | $180.3M | $140.7M | ||
| Q4 24 | $240.7M | $177.5M | ||
| Q3 24 | $254.6M | $187.5M | ||
| Q2 24 | $272.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | $346.0M | ||
| Q1 25 | $5.4M | $330.0M | ||
| Q4 24 | $5.4M | $300.0M | ||
| Q3 24 | $13.2M | $300.0M | ||
| Q2 24 | $13.2M | $319.0M |
| Q1 26 | $683.0M | — | ||
| Q4 25 | $686.0M | $2.0B | ||
| Q3 25 | $697.7M | — | ||
| Q2 25 | $690.0M | $1.9B | ||
| Q1 25 | $686.1M | $2.0B | ||
| Q4 24 | $690.5M | $2.1B | ||
| Q3 24 | $712.7M | $2.1B | ||
| Q2 24 | $736.3M | $2.1B |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | $2.6B | ||
| Q1 25 | $1.1B | $2.6B | ||
| Q4 24 | $1.1B | $2.7B | ||
| Q3 24 | $1.1B | $2.7B | ||
| Q2 24 | $1.1B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | 0.18× | ||
| Q1 25 | 0.01× | 0.16× | ||
| Q4 24 | 0.01× | 0.14× | ||
| Q3 24 | 0.02× | 0.14× | ||
| Q2 24 | 0.02× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MTUS
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
